Prosecution Insights
Last updated: November 04, 2026
Application No. 18/834,799

FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS

Non-Final OA §102§DOUBLEPATENT
Filed
Jul 31, 2024
Priority
Feb 03, 2022 — IN 202241005915 +1 more
Examiner
CHENG, KAREN
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Exelixis Inc.
OA Round
1 (Non-Final)
76%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 76% — above average
76%
Career Allowance Rate
536 granted / 702 resolved
+16.4% vs TC avg
Strong +26% interview lift
Without
With
+26.2%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
38 currently pending
Career history
735
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
27.7%
-12.3% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
32.1%
-7.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 702 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Claims 1-12, 16-17, 19, 23-25 and 27 are currently pending in the instant application. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, drawn to claims 1-12, 16-17, 19 and 23-25 with election of species PNG media_image1.png 132 214 media_image1.png Greyscale in the reply filed on 08/12/2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim 27 is withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 08/12/2026. In accordance with the MPEP, if upon examination of the elected species, no prior art is found that would anticipate or render obvious the instant invention based on the elected species and the claims drawn to the elected species are allowable, the search of the Markush-type claim will be extended (see MPEP 803.02). If prior art is then found that anticipates or renders obvious the non-elected species, the Markush-type claim will be rejected. It should be noted that the prior art search will not be extended unnecessarily to cover all non-elected species. Should Applicant overcome the rejection by amending the claim, the amended claim will be reexamined. Id. The prior art search will be extended to the extent necessary to determine patentability of the Markush-type claim. Id. In the event prior art is found during reexamination that renders obvious or anticipates the amended Markush-type claim, the claim will be rejected and the action made final. Id. Applicant's elected species appears allowable over the prior art of record. Therefore, the search of the Markush-type claim has been extended to the non-elected species of PNG media_image2.png 112 279 media_image2.png Greyscale . As prior art has been found which anticipates the above identified nonelected species, the Markush-type claims are rejected as follows and the subject matter of the claims drawn to nonelected species held withdrawn from consideration. Claims 1-8, 11-12, 16-17 and 23-25 have been examined to the extent that they are readable on the elected embodiment and the above identified nonelected species. Since art was found on the nonelected species, subject matter not embraced by the elected embodiment or the above identified nonelected species is therefore withdrawn from further consideration. The remaining subject matter of claims 9-10 and 19 that are not drawn to the above elected invention stand withdrawn under 37 CFR 1.142(b) as being non-elected subject matter. The remaining compounds which are not within the elected invention are independent and distinct from the elected invention as they differ in structure and composition. Therefore the compounds, which are withdrawn, have been restricted as the withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference, which anticipates one group, would not render obvious the other. Thus all claims containing compounds falling outside the search strategy of the elected compound and structure shown above are heretofore directed to non-elected subject matter and are withdrawn from consideration under 35 U.S.C. § 121 and 37 C.FR. § 1.142(b). A complete reply to the non-final rejection must include cancellation of non-elected claims include cancellation of non-elected claims or other appropriate action (37 CFR 1.144). See MPEP § 821.01. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b). If one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Priority PNG media_image3.png 72 392 media_image3.png Greyscale Information Disclosure Statement Applicant's Information Disclosure Statements filed on 07/31/2024, 06/05/2025, 08/12/2026 have been considered. Please refer to Applicant's copies of the 1449 submitted herewith. Claim Objections Claim 1 is objected to because of the following informalities: it recites a compound “for” formula (I) rather than a compound “of” formula (I). Appropriate correction is required. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-8, 11-12, 16-17 and 23-25 is/are rejected under 35 U.S.C. 102(a)(2) as being anticipated by WU (see WIPO Pub No. 2023/083297, pub. 05/19/2023 and filed 11/11/2022, which claims priority to PCT/CN2021/130289, filed 11/12/2021, cited in IDS filed 06/05/2025). WU teaches compounds of formula PNG media_image4.png 136 356 media_image4.png Greyscale (see p. 1) with compounds such as PNG media_image5.png 158 398 media_image5.png Greyscale (see Table 1, p. 83) exemplified. This particular compound corresponds to a compound of formula (I) wherein ring A is heterocyclyl in particular, PNG media_image6.png 106 94 media_image6.png Greyscale wherein Z1 and Z2 are N, m is 2, R1 is cycloalkyl or alkoxy, X3 and X4 are N, X1 and X2 are C, two R2 on the same carbon atom represents an oxo (=O) group,n is 2, p is 1, R4 and R5 are independently H, p is 1, Y1, Y2, Y3 and Y4 are CRy, Ry is H, R3 is substituted heterocyclyl, wherein any substituent on the heterocyclyl group is alkyl or haloalkyl. Table 1 of WO ‘297 exemplifies multiple other compounds that read on the instant claims. Further, compound 1 of WO ‘297 corresponds to compound 12 of claim 24. The compounds are taught in pharmaceutical compositions (see p. 94). Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1-8, 11-12, 16-17 and 23-25 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 3-4, 8-11, 29,31, 34, 45, 51, 54 and 92-93 of copending Application No. 18/708,755 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because ‘755 is drawn to compounds, pharmaceutical compositions comprising compounds of formula PNG media_image7.png 160 356 media_image7.png Greyscale . The compounds of ‘755 overlap in scope with those of the instant claims. For example claim 4 of ‘755 teaches that PNG media_image8.png 112 296 media_image8.png Greyscale which is taught in instant claim 12. Further claim 92 of ‘755 teaches compounds such as PNG media_image9.png 78 172 media_image9.png Greyscale which is also found in instant claim 23. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KAREN CHENG whose telephone number is (703)756-4699. The examiner can normally be reached M-F, 9AM-6PM PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Milligan can be reached at 571-270-7674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KAREN CHENG/Primary Examiner, Art Unit 1623 /ANAND U DESAI/Supervisory Patent Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 31, 2024
Application Filed
Oct 15, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780822
CRYSTALLINE FORM OF NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
2y 2m to grant Granted Nov 03, 2026
Patent 12759988
COMPOUND FOR TREATING DISEASES RELATED TO CEREBRAL ISCHEMIC INJURY
2y 8m to grant Granted Oct 13, 2026
Patent 12709619
SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR
4y 10m to grant Granted Aug 18, 2026
Patent 12698281
THIAZOLE DERIVATIVES FOR THERAPEUTIC USE
2y 11m to grant Granted Aug 04, 2026
Patent 12673039
METHODS OF INDUCING AUTOPHAGY USING COUMARIN DERIVATIVES AND RELATED COMPOUNDS
4y 11m to grant Granted Jul 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
76%
Grant Probability
99%
With Interview (+26.2%)
2y 1m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 702 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month